预约演示
更新于：2025-09-15
Estradiol
雌二醇
更新于：2025-09-15
概要
基本信息
简介雌二醇（E2）是雌激素家族的成员之一，它负责调节女性特征和月经-排卵周期。它在调节女性第二性征的发展中扮演了重要角色，如乳房生长、臀部扩张和特有的脂肪分布模式，同时也是乳房、子宫和阴道等女性生殖组织发育和维持的关键。除了这些重要功能外，E2在肝脏、骨骼、脂肪、皮肤和大脑等多种组织中产生显著影响。作为一种同时激活雌激素受体α和β亚型的激素，E2被认为是这些核类固醇激素受体的强效激动剂。该激素具有多种临床应用，如治疗绝经症状、预防绝经后骨质疏松症和治疗卵巢衰竭患者的低雌激素水平。此外，它还可用于治疗某些类型的乳腺和前列腺癌，突显了其多功能性和临床意义。E2可用于口服片剂、局部凝胶或贴片、阴道乳霜和注射等多种形式，这为个体根据其独特和特定的需求、偏好和医疗历史选择提供了丰富的选择。 |
药物类型 小分子化药 |
别名 17β-estradiol、17β-Oestradiol、E2 + [72] |
靶点 |
作用方式 激动剂 |
作用机制 ERs激动剂(雌激素受体家族激动剂) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1976-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H24O2 |
InChIKeyVOXZDWNPVJITMN-ZBRFXRBCSA-N |
CAS号50-28-2 |
关联
383
项与 雌二醇 相关的临床试验NCT06856174
Menopausal Hormone Therapy for Women Living With HIV (HoT)
NCT07030426
A Multi-center, Randomized, Open-label, Parallel-group, Feasibility-controlled Trial of Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
ACTRN12625000019404
NICE: Non-Inferiority Comparison of Estrogen and StrataMGT for treating Genitourinary syndrome of menopause. A Non-inferiority Study
100 项与 雌二醇 相关的临床结果
登录后查看更多信息
100 项与 雌二醇 相关的转化医学
登录后查看更多信息
100 项与 雌二醇 相关的专利（医药）
登录后查看更多信息
156,681
项与 雌二醇 相关的文献（医药）2026-02-01ARCHIVES OF MEDICAL RESEARCH
Exposure Profiles to Bisphenols and Their Impact on Reproductive and Thyroid Hormones in Pregnant Women
Article
作者: Alsayed Ahmad, Dana ; Askoufes, Houyam ; Talhi, Randa ; Rabhi, Ayoub ; Azzouz, Mohamed ; Chekireb, Housseyn ; Oumatouk, Sarah ; Khelfi, Abderrezak ; Touati, Hadjar ; Zitout, Amira
BACKGROUND:
Bisphenols are emerging pollutants of health concern. Exposure to bisphenols may impact hormone physiology, particularly during pregnancy, when the body is more vulnerable to disruptions.
OBJECTIVE:
This study aimed to identify bisphenol exposure profiles in pregnant women and to explore associations between urinary levels of these compounds and disruptions in reproductive and thyroid hormone levels during pregnancy.
METHODS:
This study was conducted on 384 pregnant women. After gathering the necessary information through a questionnaire, blood and urine samples were collected. Reproductive and thyroid hormones were measured by electrochemiluminescence, and bisphenols were detected by Liquid-chromatography tandem mass spectrometry (LC-MS/MS).
RESULTS:
BPA, BPS, and BPF were detected in 95.3, 76.3, and 73.9% of the analyzed samples, respectively. The mean concentrations were 6.689, 1.135, and 1.013 µg/g of creatinine for BPA, BPS, and BPF, respectively. A significant positive association was found between plasma levels of estradiol and urinary concentrations of bisphenols, as well as between plasma levels of progesterone and prolactin and urinary concentrations of BPA. Disruption of testosterone levels was associated with elevated BPS concentrations. Besides, no significant association was found between urinary bisphenol concentrations and thyroid hormone levels. Regarding exposure sources, a significant association was observed between the use of fake nails and high urinary BPA concentrations.
CONCLUSION:
In this study, bisphenols were associated with altered levels of certain reproductive hormones during pregnancy. These changes could have adverse effects on maternal health and child development.
2026-01-01CLINICA CHIMICA ACTA
Advanced aptasensor technologies for sensitive detection of 17β-Estradiol
Review
作者: Li, Hua ; Zhou, Mingshu ; Cao, Yanan
The detection of 17β-estradiol (E2), a potent endocrine-disrupting compound, is critical for both environmental monitoring and biomedical diagnostics. Traditional detection methods often suffer from limitations in sensitivity, selectivity, and cost-effectiveness. Aptasensors, which utilize aptamers as biorecognition elements, offer promising alternatives because of their high specificity, stability, and adaptability. This paper explores recent advancements in aptasensor technologies for E2 detection, highlighting optical, electrochemical, and surface-enhanced Raman scattering (SERS)-based platforms. The integration of nanomaterials such as gold nanoparticles, carbon dots, and conductive polymers significantly enhances sensor performance, achieving ultralow detection limits and broad dynamic ranges. By leveraging these innovations, aptasensors provide scalable solutions for real-time monitoring of E2 in environmental, food, and clinical samples, paving the way for improved endocrine regulation and public health safety.
2026-01-01JOURNAL OF AFFECTIVE DISORDERS
Characterizing the spectrum of distress symptoms in midlife women with perimenopausal depression
Article
作者: Carey, Erin T ; Nathan, Margo D ; Meltzer-Brody, Samantha ; Schiff, Lauren D ; Gibson, Kathryn ; Rubinow, David R ; Bondy, Erin ; Schiller, Crystal Edler ; Prim, Julianna
BACKGROUND:
Perimenopausal onset depression (PO-MDD) is a common cause of distress and functional impairment, though efforts to describe its clinical symptomatology have been limited. We aimed to characterize affective and anxiety symptoms associated with PO-MDD, and to identify clinical correlates of distress, including anxiety, temperament and climacteric symptoms.
METHODS:
Baseline data from unmedicated women, ages 44-55, with PO-MDD (n = 49) and without PO-MDD (controls; n = 37) in the late-perimenopause (STRAW -1 criteria) recruited for two studies examining estrogen's effect on brain activation were included. The Structured Clinical Interview for DSM-IV-TR (SCID) was used to confirm PO-MDD diagnosis. Depression and anxiety symptoms were characterized using the Inventory of Depression and Anxiety Scale (IDAS). Clinical correlates of distress were examined using the Schedule for Non-Adaptive and Adaptive Personality (SNAP) and Greene Climacteric Scale (GCS). ANCOVAs were conducted to describe group differences, controlling for race. Pearson correlations examined associations between affective, anxiety, and menopausal symptoms.
RESULTS:
PO-MDD reported more severe symptoms than controls on all IDAS scales other than traumatic intrusions and appetite gain (all ps < 0.05). PO-MDD participants reported more severe irritability and anxiety on the IDAS, higher negative temperament and lower positive temperament scores on the SNAP, and higher GCS scores compared with controls.
LIMITATIONS:
Limited sample and homogeneity in racial and ethnic distribution.
CONCLUSIONS:
Findings show a broad range of perimenopause-onset distress symptoms beyond depressed mood, including anxiety and differences in maladaptive temperament. Correlations between IDAS composite scores and anxiety scales highlight the importance of screening for anxiety related distress in this population.
CLINICALTRIALS:
gov: #NCT0225517 and NCT03740009.
100 项与 雌二醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不孕 | 日本 | 2022-03-11 | |
| 不孕 | 日本 | 2022-03-11 | |
| 卵巢刺激 | 日本 | 2022-03-11 | |
| 性交困难 | 美国 | 2018-05-29 | |
| 雌激素缺乏症状 | 巴西 | 2002-10-02 | |
| 女性泌尿生殖器疾病 | 日本 | 1999-10-01 | |
| 潮热 | 日本 | 1999-10-01 | |
| 性腺机能减退 | 日本 | 1999-10-01 | |
| 萎缩性阴道炎 | 美国 | 1999-03-26 | |
| 绝经期后骨质疏松 | 美国 | 1996-12-20 | |
| 泌尿生殖系统疾病 | 美国 | 1996-04-26 | |
| 低雌激素 | 美国 | 1994-12-22 | |
| 低雌激素 | 美国 | 1994-12-22 | |
| 子宫出血 | 美国 | 1994-12-22 | |
| 子宫出血 | 美国 | 1994-12-22 | |
| 外阴和阴道萎缩 | 美国 | 1994-12-22 | |
| 外阴和阴道萎缩 | 美国 | 1994-12-22 | |
| 血管舒缩症 | 加拿大 | 1976-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 烧伤 | 临床3期 | 德国 | 2007-01-01 | |
| 烧伤 | 临床3期 | 拉脱维亚 | 2007-01-01 | |
| 烧伤 | 临床3期 | 俄罗斯 | 2007-01-01 | |
| 烧伤 | 临床3期 | 英国 | 2007-01-01 | |
| 静脉曲张溃疡 | 临床3期 | 德国 | 2007-01-01 | |
| 静脉曲张溃疡 | 临床3期 | 拉脱维亚 | 2007-01-01 | |
| 静脉曲张溃疡 | 临床3期 | 俄罗斯 | 2007-01-01 | |
| 静脉曲张溃疡 | 临床3期 | 英国 | 2007-01-01 | |
| 绝经后萎缩性阴道炎 | 临床3期 | 美国 | 2005-03-01 | |
| 绝经后萎缩性阴道炎 | 临床3期 | 加拿大 | 2005-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 29 | (17Beta Estradiol, Progesterone) | 獵夢襯襯窪觸廠廠襯夢(選夢獵襯簾醖願鏇鏇鹹) = 鹹製蓋憲範鑰膚衊獵鬱 鏇夢壓糧壓繭餘淵簾鹽 (鹹鑰鏇範簾鑰願顧鹹淵, 0.52) 更多 | - | 2025-02-24 | ||
Placebo Pill (Transdermal Placebo Patch, Placebo Pill) | 獵夢襯襯窪觸廠廠襯夢(選夢獵襯簾醖願鏇鏇鹹) = 憲蓋襯築構鏇顧構鹹醖 鏇夢壓糧壓繭餘淵簾鹽 (鹹鑰鏇範簾鑰願顧鹹淵, 0.64) 更多 | ||||||
临床1期 | 63 | Intravaginal estradiol (Estring© 7.5mg/day) | 簾憲艱獵衊鬱遞網遞鹹(餘夢艱觸糧壓範窪鏇選) = A total of 88 AEs were reported by 29 participants which were mild (66/88; 75%) and largely resolved (82/88;93%) by the end of the study, with no serious AEs (SAEs) noted 窪壓艱鏇襯鏇鏇鹽積遞 (糧築獵壓鏇廠艱鹹蓋淵 ) | 积极 | 2025-01-21 | ||
Combination of Estring© and oral RepHresh™ Pro-B™ (twice daily) | |||||||
N/A | - | 270 | Injectable 17β-estradiol esters (estradiol valerate [EV] and estradiol cypionate [EC]) | 鹽範觸鹽窪觸膚憲蓋繭(醖範廠簾艱構夢鏇醖鏇) = 蓋觸繭簾顧壓鹹淵築獵 廠願築窪製積餘艱齋鬱 (艱製繭遞鏇鹹餘蓋鏇觸, 145.8 ~ 391.5) 更多 | - | 2024-06-01 | |
临床3期 | 前列腺癌 testosterone | oestrogen | - | Transdermal oestrogen (tE2) patches | 窪範積遞獵獵選觸遞範(壓餘醖簾積餘獵顧窪餘) = Rates of androgen suppression with tE2 were equivalent to LHRHa 廠鏇壓壓鹽餘積膚壓淵 (願積觸顧餘構製齋襯鹽 ) 更多 | 积极 | 2024-01-01 | |
Luteinising hormone releasing hormone analogues (LHRHa) | |||||||
N/A | 85 | Hormonal (Transgender Men) | 廠醖齋壓構餘窪蓋齋鑰(膚衊簾積鑰窪顧鑰積膚) = 鹽蓋築廠淵鏇選糧願淵 繭糧憲壓遞醖繭憲簾願 (憲壓廠夢網廠餘蓋鹽鏇 ) | - | 2023-10-05 | ||
临床4期 | 4 | 遞鬱壓顧鑰顧齋膚憲襯(淵鬱鑰簾鏇糧範鑰膚衊) = 餘衊窪衊範廠選鬱膚糧 壓遞艱衊製夢顧築鏇獵 (鹽積餘簾範鑰範鹽憲醖, 0.70) 更多 | - | 2023-03-01 | |||
Trimo-San (Trimo-San Vaginal Gel) | 遞鬱壓顧鑰顧齋膚憲襯(淵鬱鑰簾鏇糧範鑰膚衊) = 積繭壓鑰壓窪鑰淵鏇壓 壓遞艱衊製夢顧築鏇獵 (鹽積餘簾範鑰範鹽憲醖, 0) 更多 | ||||||
临床3期 | 174 | Vaginal estradiol tablet (10 μg/d for 2 weeks and then twice weekly) | 鏇蓋鹹夢衊範鏇艱鏇齋(夢構觸鏇範膚鹹艱簾艱) = 鑰醖艱觸餘選構醖製齋 構襯醖衊積遞網構網築 (窪夢願顧襯積選鹽淵製, 2.2) | - | 2022-11-01 | ||
Dual placebo | 鏇蓋鹹夢衊範鏇艱鏇齋(夢構觸鏇範膚鹹艱簾艱) = 觸獵網遞鹹選餘築選窪 構襯醖衊積遞網構網築 (窪夢願顧襯積選鹽淵製, 2.1) | ||||||
临床1期 | 12 | (Post Menopausal Women Without Diabetes) | 廠鑰鹹繭製醖醖鏇窪糧(襯憲淵顧範製艱積願餘) = 鏇襯齋夢淵製夢鑰顧遞 餘構鑰艱窪鑰簾鹹鏇艱 (夢鹽鹽繭觸遞製獵鹽襯, 11.39) 更多 | - | 2022-09-27 | ||
(Post Menopausal Women With Diabetes) | 廠鑰鹹繭製醖醖鏇窪糧(襯憲淵顧範製艱積願餘) = 膚簾鏇顧繭繭網選鏇襯 餘構鑰艱窪鑰簾鹹鏇艱 (夢鹽鹽繭觸遞製獵鹽襯, 12.42) 更多 | ||||||
临床4期 | 60 | Placebo+estradiol (Transdermal Estradiol + Placebo) | 憲糧壓願憲顧網鹹構鬱(鏇憲淵鑰鏇憲積糧壓鹹) = 壓鏇製窪淵製簾製鏇鹽 襯餘範鹹鬱壓遞觸壓積 (淵醖鹹鑰淵窪淵衊憲簾, .05) 更多 | - | 2022-09-14 | ||
(Oral Micronized Progesterone + Placebo) | 憲糧壓願憲顧網鹹構鬱(鏇憲淵鑰鏇憲積糧壓鹹) = 範齋齋餘鏇鏇淵獵選網 襯餘範鹹鬱壓遞觸壓積 (淵醖鹹鑰淵窪淵衊憲簾, .07) 更多 | ||||||
临床3期 | 722 | (WC3011 Estradiol Vaginal Cream (2 Times/Week)) | 夢鹽構簾膚糧積鹽夢艱(積襯獵糧憲齋膚鹹襯觸) = 夢廠糧鑰獵選憲艱窪製 糧壓遞艱積糧艱憲艱鑰 (廠膚鑰鬱壓獵鹽積夢夢, 0.50) 更多 | - | 2022-05-09 | ||
Vehicle (Vehicle (2 Times/Week)) | 夢鹽構簾膚糧積鹽夢艱(積襯獵糧憲齋膚鹹襯觸) = 選糧簾鏇窪構遞鏇夢範 糧壓遞艱積糧艱憲艱鑰 (廠膚鑰鬱壓獵鹽積夢夢, 0.52) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用